Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 7 | 7 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 14 | 14 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 11 | 11 |
| 2001 | 0 | 12 | 12 |
| 2002 | 0 | 21 | 21 |
| 2003 | 0 | 21 | 21 |
| 2004 | 0 | 19 | 19 |
| 2005 | 0 | 23 | 23 |
| 2006 | 0 | 13 | 13 |
| 2007 | 0 | 22 | 22 |
| 2008 | 0 | 24 | 24 |
| 2009 | 0 | 23 | 23 |
| 2010 | 0 | 20 | 20 |
| 2011 | 0 | 24 | 24 |
| 2012 | 0 | 15 | 15 |
| 2013 | 0 | 13 | 13 |
| 2014 | 0 | 18 | 18 |
| 2015 | 0 | 19 | 19 |
| 2016 | 0 | 14 | 14 |
| 2017 | 0 | 20 | 20 |
| 2018 | 0 | 11 | 11 |
| 2019 | 0 | 17 | 17 |
| 2020 | 0 | 15 | 15 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14; 95(1):4.
-
PF-06952229, a selective TGF-?-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Sep; 9(9):103653.
-
Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur J Med Chem. 2024 Sep 05; 275:116598.
-
Prevention of Parenteral Nutrition-associated Cholestasis Using Reduced Dose Soybean Lipid Emulsion: A Multicenter Randomized Trial. J Pediatr Surg. 2024 Jul; 59(7):1369-1373.
-
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
-
Neuronally-enriched exosomal microRNA-27b mediates acute effects of ibuprofen on reward-related brain activity in healthy adults: a randomized, placebo-controlled, double-blind trial. Sci Rep. 2022 01 17; 12(1):861.
-
Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
-
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells. Mol Pharmacol. 2022 01; 101(1):1-12.
-
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 12; 163(3):473-480.
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.